JLK's AI Solution 'JLK-CTL' Passes Integrated Review for Innovative Medical Devices

JLK, a medical artificial intelligence (AI) specialist company led by CEO Kim Dongmin, announced on October 28 that its AI-powered stroke analysis solution, 'JLK-CTL,' has passed the integrated review for innovative medical devices. With this approval, JLK has demonstrated its technological capabilities in the non-contrast CT-based AI diagnostic field, significantly enhancing its prospects for business expansion through the supply of certified innovative medical device solution packages in the future.

This approval marks JLK's third successful integrated review for innovative medical devices. Along with previously designated solutions such as JBS-01K and JLK-LVO, the company has now completed a 'three-solution package' of AI tools capable of non-reimbursed prescriptions for essential imaging analyses in stroke diagnosis, including non-contrast CT, CTA, and DWI (Diffusion-Weighted Imaging).

JLK-CTL is an AI solution that rapidly and accurately predicts the presence of large vessel occlusion (LVO) using non-contrast CT (NCCT) images taken without contrast agents. Its core function is to identify suspected LVO patients early, based on non-contrast CT scans commonly used in emergency settings, thereby securing the critical treatment window.

By utilizing this solution, medical professionals can quickly select patients who require further detailed examinations such as CTA or DWI, supporting diagnostic and treatment decisions and ultimately contributing to improved patient outcomes. Additionally, it is expected to reduce unnecessary testing, alleviate patients' medical expenses, decrease national insurance expenditures, and strengthen the essential healthcare system.

Ryu Wiseon, Chief Medical Officer at JLK, stated, "JLK-CTL quantitatively presents the likelihood of large vessel occlusion, enabling medical staff to make rapid decisions on patient treatment pathways. We expect that the three-solution stroke AI package, which supports various imaging modalities, will provide consistent analysis results regardless of hospital size or region, thereby helping to reinforce essential national healthcare services."

JLK anticipates that this integrated review designation for innovative medical devices will not only validate its technological prowess in the AI diagnostic field but also increase the potential for business expansion and revenue growth through the supply of innovative medical device packages. The company plans to boost sales by expanding the supply of AI solution packages tailored to hospital imaging diagnostic environments.

Kim Dongmin, CEO of JLK, commented, "With the approval of JLK-CTL as an innovative medical device, our AI technology has been officially recognized even in the non-contrast CT-based diagnostic field. We will continue to enhance our sales competitiveness by providing a variety of innovative medical device solutions as integrated packages in clinical settings, and further develop our solutions to deliver social value by improving patient outcomes, contributing to national insurance finances, and supporting essential medical services."